真实世界数据中抗纤维化药物剂量模式与IPF临床结局的关联
该回顾性研究利用美国两个数据源分析IPF患者抗纤维化药物剂量调整与疾病进展的关系,发现剂量减少和停药常见,但调整剂量与持续足量治疗相比疾病进展风险无显著差异,各队列进展事件率均较高。
要点
- IPF患者中抗纤维化药物剂量减少或停药常见,多因耐受性差。
- 调整剂量与足量治疗相比,疾病进展风险无显著差异。
- 各剂量组疾病进展事件率均较高,提示需要更有效且耐受性更好的疗法。
核心结论
- IPF患者中抗纤维化药物剂量减少和停药常见,可能源于药物耐受性差。
- 无论抗纤维化给药策略如何,两个队列中均有相当比例患者出现疾病进展。
- 剂量减少或停药与持续足量治疗相比,至进展时间无显著差异。
研究设计与样本
- 回顾性研究,分析美国多中心肺纤维化基金会患者登记处(Registry)和杜克大学健康系统电子健康记录(EHR)中启动抗纤维化治疗的IPF患者数据。
- 剂量分组为足量、剂量减少≥3个月或停止治疗≥3个月,作为时间依赖暴露。
- 采用Cox比例风险模型分析剂量组与IPF进展的关联,并校正人口学和肺功能。
主要发现
- Registry中位随访30.0(17.5/30.0)个月,EHR中位随访14.0(7.4/29.6)个月。
- Registry中347/545(63.7%)患者维持足量,EHR中609/1,027(59.3%)维持足量。
- Registry中每100人年进展事件率:足量39.74、减量46.62、停药70.69;EHR中分别为44.82、40.46、41.72。
临床怎么用
- 临床中应关注IPF患者抗纤维化药物的耐受性,剂量调整常见但可能不显著改变疾病进展风险。
- 即使调整剂量,仍需密切监测疾病进展,因各剂量组进展事件率均较高。
局限性
- 回顾性研究设计可能存在残余混杂。
- 两个数据源随访时间不同,EHR随访较短。
- 剂量分组基于≥3个月的定义,可能忽略更短期的调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antifibrotic therapies nintedanib and pirfenidone slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF). However, both medications are often poorly tolerated, leading to dose reductions and discontinuations in practice. RESEARCH QUESTION: How do antifibrotic dose changes (reductions or cessations) affect disease progression in IPF? STUDY DESIGN AND METHODS: This retrospective study analyzed data for patients with IPF who initiated antifibrotic therapy using two US data sources: the multicenter Pulmonary Fibrosis Foundation Patient Registry (Registry) and Duke University Health System electronic health records (EHR). Antifibrotic dose groups were defined as full dose, reduced dose for ≥3 months, or stopped therapy for ≥3 months. Associations between antifibrotic dose group, a time-varying exposure, and IPF progression, defined as composite ≥10% decline in ppFVC, all-cause hospitalization, lung transplant, or death, were analyzed by Cox proportional-hazards models adjusted for demographics and lung function. RESULTS: Over a median (25th/75th percentile) follow-up of 30.0 (17.5/30.0) months in the Registry and 14.0 (7.4/29.6) months in the EHR, 347/545 (63.7%) and 609/1,027 (59.3%) patients remained on full dose, respectively. Event rates for progression per 100 person-years in patients on full dose, reduced dose, or discontinuation were 39.74, 46.62, and 70.69, respectively, in the Registry and 44.82, 40.46, and 41.72 in the EHR. Time to progression did not differ significantly between patients who reduced or stopped antifibrotics and those who remained on full dose in the Registry (HR 1.17 [95% CI 0.90-1.52] for dose reduction, 1.51 [1.04-2.18] for discontinuation; P=.073) and EHR (HR 0.87 [0.69-1.09], 0.94 [0.66-1.36]; P=.476), respectively. INTERPRETATION: Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability. Disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-tolerated IPF therapies.
引用
- Swaminathan AC, Stevens SR, Chopra P, et al. Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources. Chest. 2026. PMID: 42810431. doi:10.1016/j.chest.2026.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。